Kishore M Gadde1, Glen L Xiong
1Duke University Medical Centre, Box 3292, Durham, NC 27710, USA. gadde001@mc.duke.edu
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Bupropion, a norepinephrine and dopamine reuptake inhibitor, shows efficacy for weight loss in obese patients, despite not being FDA-approved for this indication. This review covers its pharmacology, clinical evidence, and role in obesity management.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: